Masimo (MASI) Competitors $173.16 -2.91 (-1.65%) As of 01/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MASI vs. RMD, IDXX, DXCM, STE, PODD, HOLX, BAX, GMED, TFX, and ITGRShould you be buying Masimo stock or one of its competitors? The main competitors of Masimo include ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), STERIS (STE), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), Teleflex (TFX), and Integer (ITGR). These companies are all part of the "health care equipment" industry. Masimo vs. ResMed IDEXX Laboratories DexCom STERIS Insulet Hologic Baxter International Globus Medical Teleflex Integer ResMed (NYSE:RMD) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking. Is RMD or MASI more profitable? ResMed has a net margin of 23.15% compared to Masimo's net margin of 3.85%. ResMed's return on equity of 25.53% beat Masimo's return on equity.Company Net Margins Return on Equity Return on Assets ResMed23.15% 25.53% 17.59% Masimo 3.85%14.98%6.95% Do insiders & institutionals believe in RMD or MASI? 55.0% of ResMed shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 9.7% of Masimo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, RMD or MASI? ResMed has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Masimo has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Do analysts prefer RMD or MASI? ResMed presently has a consensus price target of $233.09, suggesting a potential downside of 5.77%. Masimo has a consensus price target of $179.67, suggesting a potential upside of 3.76%. Given Masimo's stronger consensus rating and higher probable upside, analysts clearly believe Masimo is more favorable than ResMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ResMed 1 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.43Masimo 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has stronger earnings & valuation, RMD or MASI? ResMed has higher revenue and earnings than Masimo. ResMed is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioResMed$4.69B7.75$1.02B$7.5532.76Masimo$2.05B4.53$81.50M$1.45119.42 Does the media prefer RMD or MASI? In the previous week, Masimo had 22 more articles in the media than ResMed. MarketBeat recorded 37 mentions for Masimo and 15 mentions for ResMed. ResMed's average media sentiment score of 1.18 beat Masimo's score of 0.46 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Masimo 7 Very Positive mention(s) 7 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor RMD or MASI? Masimo received 37 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 63.86% of users gave Masimo an outperform vote while only 52.66% of users gave ResMed an outperform vote. CompanyUnderperformOutperformResMedOutperform Votes42652.66% Underperform Votes38347.34% MasimoOutperform Votes46363.86% Underperform Votes26236.14% SummaryResMed and Masimo tied by winning 9 of the 18 factors compared between the two stocks. Get Masimo News Delivered to You Automatically Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MASI vs. The Competition Export to ExcelMetricMasimoElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.27B$3.54B$5.39B$9.24BDividend YieldN/A1.66%5.37%3.99%P/E Ratio119.4219.0389.1117.52Price / Sales4.5370.791,221.8479.25Price / Cash29.8937.2343.6036.96Price / Book6.713.955.014.72Net Income$81.50M$94.49M$117.81M$224.61M7 Day Performance0.63%2.18%2.03%1.55%1 Month Performance2.15%4.09%4.03%5.12%1 Year Performance37.90%3.77%26.78%21.25% Masimo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MASIMasimo4.2204 of 5 stars$173.16-1.7%$179.67+3.8%+37.9%$9.27B$2.05B119.425,200Analyst ForecastNews CoverageRMDResMed4.5129 of 5 stars$239.89+1.2%$233.09-2.8%+39.9%$35.22B$4.69B31.779,980Upcoming EarningsPositive NewsIDXXIDEXX Laboratories4.6748 of 5 stars$419.26-2.2%$523.86+24.9%-19.0%$34.33B$3.66B40.4311,000Positive NewsDXCMDexCom4.9646 of 5 stars$84.38-0.5%$99.29+17.7%-32.6%$32.96B$3.62B50.539,600STESTERIS4.7448 of 5 stars$209.50-0.3%$262.50+25.3%-0.7%$20.68B$5.14B47.8318,179News CoveragePositive NewsPODDInsulet4.4903 of 5 stars$275.81+1.1%$272.81-1.1%+35.4%$19.35B$1.70B47.233,000Insider TradePositive NewsHOLXHologic4.7949 of 5 stars$69.73-0.3%$88.92+27.5%-3.8%$15.82B$4.03B20.947,063Analyst RevisionHigh Trading VolumeBAXBaxter International4.711 of 5 stars$30.99+0.1%$40.45+30.6%-17.6%$15.82B$14.81B154.9460,000News CoverageGMEDGlobus Medical4.4167 of 5 stars$90.84+0.4%$96.91+6.7%+66.5%$12.37B$2.48B135.575,000Analyst RevisionPositive NewsHigh Trading VolumeTFXTeleflex4.7906 of 5 stars$181.56+0.1%$252.50+39.1%-28.5%$8.43B$2.97B36.1014,500ITGRInteger1.6284 of 5 stars$140.91+0.3%$145.44+3.2%+36.5%$4.73B$1.71B43.4910,500 Related Companies and Tools Related Companies ResMed Alternatives IDEXX Laboratories Alternatives DexCom Alternatives STERIS Alternatives Insulet Alternatives Hologic Alternatives Baxter International Alternatives Globus Medical Alternatives Teleflex Alternatives Integer Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MASI) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Masimo Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Masimo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
